

MT2022-56: A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of multiple myeloma after 3 or more previous treatments - able to complete activities of daily living with minimal help

Exclusion Criteria:

- history of significant heart disease - low red or white blood counts - abnormal liver function tests

Conditions & Interventions

Interventions:

Drug: Bendamustine, Drug: Cyclophosphamide, Drug: Daratumumab, Drug: FT576 (Allogenic CAR NK cells with BCMA expression), Drug: Fludarabine

Conditions:

Cancer

Keywords:

Multiple Myeloma, Myeloma, Clinics and Surgery Center (CSC)

More Information

Description: The purpose of this study is to test the safety of FT576 at different doses and schedules and to understand the way the body processes and responds to FT576. The study will also find out what effects FT576, when given alone (also called monotherapy) or in combination with an anti-cancer drug (called a monoclonal antibody), may have on you and your cancer. FT576 is a type of cell product made up of "natural killer" or NK cells. NK cells are a type of immune blood cell that are known to attack cancer cells.

Study Contact: Aimee Merino - merin008@umn.edu

Principal Investigator: Aimee Merino

IRB

Number: SITE00001809

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.